Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
- 30 November 2009
- journal article
- research article
- Published by Elsevier BV in The Lancet Neurology
- Vol. 8 (11), 987-997
- https://doi.org/10.1016/s1474-4422(09)70237-6
Abstract
No abstract availableFunding Information
- Bayer Schering
This publication has 36 references indexed in Scilit:
- Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteriaMultiple Sclerosis Journal, 2009
- MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndromeBMC Neurology, 2009
- MRI as an outcome in multiple sclerosis clinical trialsNeurology, 2009
- Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosisBrain, 2008
- A Novel Bioassay for the Determination of Neutralizing Antibodies to IFNβ1bJournal of Interferon & Cytokine Research, 1998
- Validation of the Functional Assessment of Multiple Sclerosis quality of life instrumentNeurology, 1996
- Cognitive dysfunction in multiple sclerosis.Neurology, 1991
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983